Immune Checkpoint Blockade Therapy May Be a Feasible Option for Primary Pulmonary Lymphoepithelioma-like Carcinoma.
Immune Checkpoint Blockade Therapy May Be a Feasible Option for Primary Pulmonary Lymphoepithelioma-like Carcinoma.
复制标题
DOI：
10.3389/fonc.2021.626566
复制
发表时间：
2021
影响因子：
4.7
通讯作者：
Chen B
中科院分区：
文献类型：
--
作者：
Wu Z;Xian X;Wang K;Cheng D;Li W;Chen B
原发性肺淋巴上皮瘤样癌（PPLELC）是非小细胞肺癌（NSCLC）的一种罕见亚型，目前尚无公认的治疗方法。最近，在 PPLELC 中观察到了有利的免疫检查点阻断反应。本研究旨在回顾该方案对晚期 PPLELC 患者的效果。回顾性分析2008年1月至2019年12月期间在华西医院接受免疫检查点抑制剂治疗的PPLELC患者。检索并审查了人口统计参数和抗肿瘤治疗细节。在 128 名诊断为 PPLELC 的患者中，有 5 名晚期接受免疫检查点抑制剂的患者被纳入分析。所有这些患者均为非吸烟女性，诊断时中位年龄为 55.6 岁（范围 53-58）。他们的 PD-L1 表达中位数为 40%（范围为 30-80%）。尽管患者接受了手术、化疗和放疗，但所有治疗均无效。免疫检查点抑制剂进行姑息治疗，三名患者反应良好，最佳总体反应为部分缓解（PR）。因此，免疫检查点抑制剂可能是晚期 PPLELC 的一种有前景的治疗方法，需要进行大型临床试验来获得有关该方案的更多证据。
Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) is a rare subtype of non-small cell lung cancer (NSCLC) for which there is currently no recognized treatment. Recently, favorable immune checkpoint blockade responses have been observed in PPLELC. This study aimed to review the effects of this regimen in patients with advanced PPLELC. PPLELC patients treated with immune checkpoint inhibitors at West China Hospital between January 2008 and December 2019 were retrospectively identified. Demographic parameters and antitumor treatment details were retrieved and reviewed. Among 128 patients diagnosed with PPLELC, 5 who received immune checkpoint inhibitors at advanced stages were included in the analysis. All of these patients were female nonsmokers with a median age of 55.6 (range 53-58) years at diagnosis. Their median PD-L1 expression was 40% (range, 30-80%). Although the patients underwent surgeries, chemotherapy and radiotherapy, all the treatments failed. Immune checkpoint inhibitors were administered palliatively, and three patients responded favorably, with the best overall response being partial remission (PR). Thus, immune checkpoint inhibitors may be a promising treatment for advanced PPLELC, and large clinical trials are warranted to obtain more evidence regarding this regimen.
登录
查看更多内容
影响因子：
14
作者：
Gurung, Smriti;Khan, Fatima;Lee, Byungheon
通讯作者：
Lee, Byungheon
影响因子：
3.5
作者：
Han, AJ;Xiong, M;Zong, YS
通讯作者：
Zong, YS
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
4
作者：
Cheng, Ying;Han, Baohui;Zhu, Jing
通讯作者：
Zhu, Jing
影响因子：
2.5
作者：
He, Jiaxi;Shen, Jianfei;He, Jianxing
通讯作者：
He, Jianxing